Biodistribution, pharmacokinetics, and organ-level dosimetry for (188)Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans

BACKGROUND: Rhenium-188-labelled-Lipiodol radioembolization is a safe and cost-effective treatment for primary liver cancer. In order to determine correlations between treatment doses and patient response to therapy, accurate patient-specific dosimetry is required. Up to date, the reported dosimetry...

Descripción completa

Detalles Bibliográficos
Autores principales: Esquinas, Pedro L., Shinto, Ajit, Kamaleshwaran, Koramadai K., Joseph, Jephy, Celler, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283804/
https://www.ncbi.nlm.nih.gov/pubmed/30523435
http://dx.doi.org/10.1186/s40658-018-0227-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283804/
https://www.ncbi.nlm.nih.gov/pubmed/30523435
http://dx.doi.org/10.1186/s40658-018-0227-6

Ejemplares similares